Tumor necrosis factor (TNF) inhibitor (TNFi) therapy, commonly used to treat autoimmune conditions, such as ankylosing spondylitis (AS), rheumatoid arthritis, and psoriatic arthritis, has been associated with the development of drug-induced lupus (DIL). This evidence concerns the gene TNF and psoriatic arthritis.